Document:

cue-ex105_733.htm

Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed.  Double asterisks denote omissions.

 

EXHIBIT 10.5

THIRD Amendment

to Collaboration, LICENSE and Option Agreement

This Third Amendment to the Collaboration, License and Option Agreement (the “Third Amendment”) is entered into as of October 29, 2019 (the “Third Amendment Effective Date”) by and between Cue Biopharma, Inc., a Delaware corporation, having an address of 21 Erie Street, Cambridge, MA 02139 (“Cue”), and LG Chem Ltd., with its principal place of business at LG Twin Towers, 128, Yeoui-daero, Yeongdeungpo-gu, Seoul, 07336, Republic of Korea (“LGC”). Cue and LGC may be referred to herein individually as a “Party” or collectively as the “Parties”. 

Whereas, the Parties entered into a Collaboration, License and Option Agreement as of November 6, 2018 (the “Original Agreement”) that was subsequently amended on March 15, 2019 and August 5, 2019 (the “First Amendment” and “Second Amendment”, and the Original Agreement, collectively the “Agreement”); 

Whereas, Section 4.3(c) of the Agreement establishes a term for the Parties to (i) select a Collaboration Antigen and Initial Collaboration Alleles for the CUE-103 Program, and (ii) prepare and approve a CUE-103 Initial Research Plan; and

Whereas, the Parties desire to further extend the terms provided in Section 4.3(c); 

Now, Therefore, in consideration of the foregoing premises and the mutual covenants contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Cue and LGC hereby agree as follows:

	
 
	
1.
	
Section 4.3(c) of the Agreement is hereby deleted in its entirety and replaced with the following in lieu thereof:

	
 
	
(c)
	
CUE-103 Program.

(i) Antigen and Allele Selection. No later than [**] and no sooner than [**] (the “CUE-103 Program Selection Period”), (i) the Parties, through the JSC, shall jointly choose one (1) Collaboration Antigen (other than a Cue Reserved Antigen) for the CUE-103 Program, (ii) LGC shall select one (1) Allele as its Initial Collaboration Allele for the CUE-103 Program, and (iii) following LGC’s selection, Cue shall select one (1) Allele as its Initial Collaboration Allele for the CUE-103 Program (whether the same or different from the Initial Collaboration Allele elected by LGC).  Each Party may select no more than one (1) Allele as its Initial Collaboration Allele for the CUE-103 Program, provided that if at any time the JSC determines that [**], the applicable Party [**].

(ii) Research Plan. No later than [**] but after the Parties’ selection of the Collaboration Antigen for the CUE-103 Program and each Party’s selection of its Initial Collaboration Alleles for the CUE-103 Program, the Parties, through the JRC, shall jointly draft, 

 

 

review, discuss and send to the JSC for approval (with neither Party unreasonably withholding its approval) the initial Research Plan (including an initial Research Budget) for the Initial Collaboration Alleles in the CUE-103 Program (such Research Plan (including the Research Budget), a “CUE-103 Initial Research Plan”). The CUE-103 Initial Research Plan shall, at a minimum, unless the Parties agree otherwise, be reasonably designed to include Research activities for CUE-103 Compounds containing the Initial Collaboration Allele(s) reasonably required to accomplish the filing of an IND [**] and shall be consistent with the Template Initial Research Plan. The CUE-103 Initial Research Plan shall be updated and amended by the JRC as it deems appropriate, and in any event promptly after any LGC Additional Allele, Cue Additional Allele [**] is added to the CUE-103 Program in accordance with the terms of Section 4.3(e).

	
 
	
2.
	
Except as amended hereby, all other terms and conditions of the Agreement shall remain in full force and effect, and are unmodified by this Third Amendment.

IN WITNESS WHEREOF the Parties hereto have caused this Third Amendment to be executed and entered into by their duly authorized representatives as of the Third Amendment Effective Date.

[The Remainder of this page is intentionally left blank. Signatures appear on following page.]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

	
Cue Biopharma, Inc.
	
 
	
LG Chem Ltd.

	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 

	
By:
	
/s/ Daniel Passeri
	
 
	
By:
	
/s/ Jeewoong Son

	
 
	
 
	
 
	
 
	
 

	
Name:
	
Daniel Passeri
	
 
	
Name:
	
Jeewoong Son

	
 
	
 
	
 
	
 
	
 

	
Title:
	
CEO
	
 
	
Title:
	
Presidentcue-ex106_730.htm

EXECUTION VERSION

 

Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed.  Double asterisks denote omissions.

 

EXHIBIT 10.6

FOURTH AMENDMENT 

TO Collaboration, LICENSE and Option Agreement

 

This Fourth Amendment to the Collaboration, License and Option Agreement (the “Fourth Amendment”) is entered into as of December 18, 2019 (the “Fourth Amendment Effective Date”), by and between Cue Biopharma, Inc., a Delaware corporation, having an address of 21 Erie Street, Cambridge, MA 02139 (“Cue”), and LG Chem Ltd., with its principal place of business at LG Twin Towers, 128, Yeoui-daero, Yeongdeungpo-gu, Seoul, 07336, Republic of Korea (“LGC”).  Cue and LGC may be referred to herein individually as a “Party” or collectively as the “Parties”.  

Whereas, the Parties entered into a Collaboration, License and Option Agreement as of November 6, 2018 (the “Original Agreement”) that was subsequently amended on March 15, 2019 (the “First Amendment”), August 5, 2019 (the “Second Amendment”) and October 29, 2019 (the “Third Amendment” and collectively with the Original Agreement, the First Amendment and the Second Amendment, the “Agreement”);  

Whereas, the Parties entered into a Global License and Collaboration Agreement on even date herewith (the “Global Agreement”); and

Whereas, the Parties desire to make the following changes to certain provisions of the Agreement.

Now, Therefore, in consideration of the foregoing premises and the mutual covenants contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Cue and LGC hereby agree as follows:

	
1.
	
All capitalized terms not separately defined in this Fourth Amendment shall have the meaning ascribed to them in the Agreement.

	
2.
	
The first three sentences of Section 4.15 of the Agreement are hereby deleted and replaced with the following:

“In order to facilitate the Development and Manufacturing activities contemplated by this Agreement, Cue shall, at LGC’s cost, provide to LGC certain available biological materials or chemical compounds in Cue’s possession and Controlled by Cue that are relevant to Collaboration Compounds or Collaboration Products (collectively, “Materials”) for use by LGC in furtherance of activities under a Research Plan, Development Plan, Manufacturing Plan, Commercialization Plan or otherwise under this Agreement. Except as otherwise provided for under this Agreement, all such Materials delivered will remain the sole property of Cue.  LGC shall use such Materials only in furtherance of activities conducted in accordance with this Agreement or the Global 

 

 

License and Collaboration Agreement, as applicable, and the Materials will not be used or delivered for any other purpose, or to or for the benefit of any Third Party, except for Sublicensees and subcontractors, without the prior written consent of Cue, and will be used in compliance with all Applicable Laws.”  

	
3.
	
The third sentence of Section 9.1(b) of the Agreement is hereby deleted and replaced with the following:

“Except as granted herein or in the Global License and Collaboration Agreement, LGC shall have no rights in the Cue Background IP or involvement in any actions taken by Cue with respect to Cue Background IP, and Cue shall have no rights in the LGC Background IP or involvement in any actions taken by LGC with respect to LGC Background IP.”

	
4.
	
The second sentence of Section 13.1 of the Agreement is hereby deleted and replaced with the following:

“Upon expiration (but not termination) of this Agreement with respect to any Collaboration Product in any country within the LGC Territory or Cue Territory, (a) LGC’s license under Section 2.1 with respect to such Collaboration Product in such country, including LGC’s right to use related Materials provided by Cue under Section 4.15 under such license, will become fully paid-up and royalty free and (b) Cue’s license under Section 2.4 with respect to such Collaboration Product in such country will become fully paid-up and royalty free.”

	
5.
	
Section 15.6(d)(i) of the Agreement is hereby deleted and replaced with the following:

“(A) following closing of a Change of Control, Transferee shall require that [**], in each case, [**] and are not [**], and the Transferee does not [**] and (B) following closing of a Change of Control, Transferee shall [**]; provided that if the requirements of either Section 15.6(d)(i)(A) or (B) are not met, [**]”

	
6.
	
Entire Agreement; Modification.  Except as expressly amended by this Fourth Amendment, all other terms and conditions of the Agreement shall remain in full force and effect, and are unmodified by this Fourth Amendment.  The Agreement, as modified by this Fourth Amendment, contains the entire agreement of the Parties with regard to the subject matter set forth herein and supersedes all prior and contemporaneous agreements and communications, whether oral, written or otherwise, concerning any and all matters contained herein; provided, however, that the Global Agreement shall continue in full force and effect in accordance with its terms.  This Fourth Amendment may only be modified or supplemented in a writing expressly stated for such purpose and signed by the Parties.

	
7.
	
Counterparts; Electronic or Facsimile Signatures.  This Fourth Amendment may be executed in any number of counterparts, each of which shall be an original, but all of which together shall constitute one instrument.  This Fourth Amendment may be executed and delivered electronically or by facsimile and upon such delivery such electronic or facsimile signature will be deemed to have the same effect as if the original signature had been delivered to the other Party.

2

 

 

[Signature Page Follows]

3

 

 

 

 

In Witness Whereof, the Parties hereto have caused this Fourth Amendment to be executed and entered into by their duly authorized representatives as of the Fourth Amendment Effective Date.

 

	
Cue Biopharma, Inc.

 
	
 
	
LG Chem Ltd.

 
	
 

	
By: 
	
/s/ Daniel Passeri
	
 
	
By: 
	
/s/ Jeewoong Son
	
 

	
Name: 
	
Daniel Passeri
	
 
	
Name: 
	
Jeewoong Son
	
 

	
Title: 
	
CEO
	
 
	
Title: 
	
President
	
 

 

 

 

 

 

 

4

 

Signature Page to Fourth Amendment to License, Collaboration and Option Agreement

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00323-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00323-of-00352.parquet"}]]